These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35501195)

  • 21. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
    Bansal A; Uriel N; Colombo PC; Narisetty K; Long JW; Bhimaraj A; Cleveland JC; Goldstein DJ; Stulak JM; Najjar SS; Lanfear DE; Adler ED; Dembitsky WP; Somo SI; Crandall DL; Chen D; Connors JM; Mehra MR
    J Heart Lung Transplant; 2019 Aug; 38(8):806-816. PubMed ID: 31147187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of Von Willebrand Factor Cleavage by adamts-13 in Patients Supported by Left Ventricular Assist Devices.
    Zhou Y; Qin S; Hilton T; Tang L; Cruz M; Hernandez R; Moake JL; Tian Q; Frazier OH; Dong JF; Nascimbene A
    ASAIO J; 2017; 63(6):849-853. PubMed ID: 28682993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
    Meyer AL; Malehsa D; Bara C; Budde U; Slaughter MS; Haverich A; Strueber M
    Circ Heart Fail; 2010 Nov; 3(6):675-81. PubMed ID: 20739614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.
    Goda M; Jacobs S; Rega F; Peerlinck K; Jacquemin M; Droogne W; Vanhaecke J; Van Cleemput J; Van den Bossche K; Meyns B
    J Heart Lung Transplant; 2013 May; 32(5):539-45. PubMed ID: 23570742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired von Willebrand syndrome associated with left ventricular assist device.
    Nascimbene A; Neelamegham S; Frazier OH; Moake JL; Dong JF
    Blood; 2016 Jun; 127(25):3133-41. PubMed ID: 27143258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective analysis of bleeding events in left ventricular assist device patients.
    Sherazi S; Kouides P; Francis C; Lowenstein CJ; Refaai M; Conley G; Johnson BA; Muchnik E; Lien S; Massey HT; Alexis JD
    Int J Artif Organs; 2018 May; 41(5):269-276. PubMed ID: 29562808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individual Variability in von Willebrand Factor Fragility in Response to Shear Stress: A Possible Clue for Predicting Bleeding Risk.
    Sakatsume K; Akiyama M; Sakota D; Hijikata W; Horiuchi H; Maruyama O; Saiki Y
    ASAIO J; 2022 Sep; 68(9):1128-1134. PubMed ID: 34967782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired platelet defects are responsible for nonsurgical bleeding in left ventricular assist device recipients.
    Arias K; Sun W; Wang S; Sorensen EN; Feller E; Kaczorowski D; Griffith B; Wu ZJ
    Artif Organs; 2022 Nov; 46(11):2244-2256. PubMed ID: 35596611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in Von Willebrand factor profile predicts clinical outcomes in patients on mechanical circulatory support.
    Oezpeker C; Zittermann A; Baurichter D; Morshuis M; Prohaska W; Kassner A; Erkilet G; Gummert J; Milting H
    J Card Surg; 2018 Oct; 33(10):693-702. PubMed ID: 30199919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
    Jilma-Stohlawetz P; Quehenberger P; Schima H; Stoiber M; Knöbl P; Steinlechner B; Felli A; Jilma B
    Thromb Res; 2016 Jan; 137():196-201. PubMed ID: 26616301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.
    Netuka I; Kvasnička T; Kvasnička J; Hrachovinová I; Ivák P; Mareček F; Bílková J; Malíková I; Jančová M; Malý J; Sood P; Sundareswaran KS; Connors JM; Mehra MR
    J Heart Lung Transplant; 2016 Jul; 35(7):860-7. PubMed ID: 27435529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients.
    Crow S; Milano C; Joyce L; Chen D; Arepally G; Bowles D; Thomas W; Ortiz NV
    ASAIO J; 2010; 56(5):441-5. PubMed ID: 20613494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors of Gastrointestinal Bleeding After Continuous Flow Left Ventricular Assist Device.
    Balcioglu O; Kemal HS; Ertugay S; Ozturk P; Engin Y; Nalbantgil S; Engin C; Yagdi T; Ozbaran M
    ASAIO J; 2018; 64(4):458-461. PubMed ID: 28957820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation.
    Davis ME; Haglund NA; Tricarico NM; Matafonov A; Gailani D; Maltais S
    ASAIO J; 2015; 61(1):e1-4. PubMed ID: 25251586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematologic effects of continuous flow left ventricular assist devices.
    Slaughter MS
    J Cardiovasc Transl Res; 2010 Dec; 3(6):618-24. PubMed ID: 20835786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.
    Deconinck S; Tersteeg C; Bailleul E; Delrue L; Vandeputte N; Pareyn I; Itzhar-Baikian N; Deckmyn H; De Meyer SF; Vanderheyden M; Vanhoorelbeke K
    Res Pract Thromb Haemost; 2018 Oct; 2(4):762-766. PubMed ID: 30397685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of pulsatility with continuous-flow left ventricular assist devices and the significance of the arterial endothelium in von-Willebrand factor production and degradation.
    Giridharan GA; Berg IC; Ismail E; Nguyen KT; Hecking J; Kirklin JK; Cheng X; Sethu P
    Artif Organs; 2023 Apr; 47(4):640-648. PubMed ID: 36404709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Toroidal-Flow Left Ventricular Assist Device Minimizes Blood Trauma: Implications of Improved Ventricular Assist Device Hemocompatibility.
    Bartoli CR; Hennessy-Strahs S; Gohean J; Villeda M; Larson E; Longoria R; Kurusz M; Acker MA; Smalling R
    Ann Thorac Surg; 2019 Jun; 107(6):1761-1767. PubMed ID: 30586577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.